ADMA Biologics, Inc.
ADMA
Key stats
- Open
- 13.23
- Day high
- 13.52
- Day low
- 13.04
- Previous close
- 13.19
- Volume
- 3.09M
- VWAP
- 13.26
- 52-week high
- 20.46
- 52-week low
- 7.21
- Market cap
- 2.93B
- Shares out
- 221.85M
- Employees
- 647
- Listed
- 2013
About ADMA Biologics, Inc.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · RAMSEY, NJ · admabiologics.com
Options · expiring Nov 20
Nov 12, 4:00 PM ET- Call open interest
- 13.9K
- Put open interest
- 1.9K
- Put/call
- 0.13
- At-the-money IV
- 35.9%
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 14 call | 0.15 | Nov 12, 3:11 PM | 157 | 694 | 46.7% |
| 11 call | 2.50 | Nov 12, 12:33 PM | 107 | 5.9K | — |
| 15 call | 0.08 | Nov 6, 3:32 PM | 62 | 1.7K | 63.9% |
| 13 call | 0.65 | Nov 12, 2:20 PM | 37 | 1.5K | 35.9% |
| 12 call | 1.80 | Nov 12, 12:06 PM | 35 | 678 | 65.5% |
| 12 put | 0.13 | Nov 11, 12:07 PM | 13 | 56 | 81.7% |
Quarterly results
Massive · Nov 4, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $141.10M | $124.39M | $114.49M | $139.16M |
| Gross profit | $99.86M | $86.28M | $80.75M | $88.82M |
| Operating income | $67.76M | $52.45M | $50.29M | $62.75M |
| Net income | $49.88M | $37.82M | $45.33M | $49.38M |
| Diluted EPS | 0.22 | 0.16 | 0.19 | 0.20 |
| Operating cash flow | $17.37M | $29.54M | $58.25M | $35.64M |
| Assets | $732.49M | $684.21M | $665.18M | $624.24M |
| Liabilities | $293.98M | $276.00M | $274.86M | $146.92M |
| Equity | $438.51M | $408.21M | $390.32M | $477.32M |
Technicals
Massive · Nov 12, 2026- 50-day average10.49
- 200-day average10.74
- RSI (14 days)68.3
Short interest
Massive · Oct 30, 2026- Oct 30, 202618.04M shares · 7.1 days to cover
- Oct 15, 202619.53M shares · 6.5 days to cover
- Sep 30, 202620.60M shares · 5.7 days to cover
- Sep 15, 202624.21M shares · 10.8 days to cover
Related companies
MassiveNews coverage
No stories about ADMA Biologics, Inc. right now.